Randomized phase 2 trial comparing JNJ‐9375, a thrombin‐directed antibody, with apixaban for prevention of venous thrombosis

Autor: Fisseha Tesfaye, Michael R. Lassen, John Strony, Renée M Swaim, Jeffrey I. Weitz, Gary Peters, Gary E. Raskob, Lee Michael, Peter M DiBattiste, Charles W. Francis, Annelise Segers, Takeshi Fuji, Robin S. Roberts

Publikováno v: Journal of Thrombosis and Haemostasis

BACKGROUND JNJ-9375 is an antibody against exosite 1 on thrombin, inhibits substrate binding but not catalytic activity. OBJECTIVE To examine the possibility that JNJ-9375 attenuates thrombosis without affecting hemostasis, we compared the efficacy a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90c0c3a1f52b1585ddf7cffee8390c2e
https://doi.org/10.1111/jth.14639

Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty

Autor: Zhong Yuan, Scott D. Berkowitz, Richard J. Friedman, Peter M DiBattiste, Jesse A. Berlin, Rachel B. Weinstein, Bennett Levitan, Martin Homering, Alexander G.G. Turpie

Publikováno v: Vascular Health and Risk Management

Bennett Levitan,1 Zhong Yuan,1 Alexander GG Turpie,2 Richard J Friedman,3 Martin Homering,4 Jesse A Berlin,1 Scott D Berkowitz,5 Rachel B Weinstein,1 Peter M DiBattiste61Janssen Research & Development, LLC, Titusville, NJ, USA; 2Hamilton Health Scien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9187e7208f01bbe48413ee7e2ab8fb7d
http://europepmc.org/articles/PMC3971939

Effects on platelet function of a direct acting antagonist of coagulation factor Xa

Autor: David J. Schneider, Sukit M. Ringwala, Peter M DiBattiste

Publikováno v: Journal of Thrombosis and Thrombolysis. 34:291-296

Because novel direct acting anticoagulants are being tested in the secondary prevention of cardiovascular events, we assessed potential effects of a direct acting antagonist of Factor Xa on platelet function. Blood from patients with known coronary a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a64771cf010c4020a771ff600a4d1ea9
https://doi.org/10.1007/s11239-012-0727-5

A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo

Autor: John Viscusi, Cong Chen, Sean P. Curtis, Peter M. DiBattiste, Tuli Ahmed, Christopher P. Cannon

Publikováno v: Archives of Drug Information. 1:4-13

OBJECTIVES: Selective cyclooxygenase (COX)-2 inhibitors are effective analgesic and anti-inflammatory agents with improved gastrointestinal safety and tolerability compared with traditional NSAIDs. However, data from long-term, placebo-controlled stu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0b7fe85a77ffd2b1a4288c1dece96c1
https://doi.org/10.1111/j.1753-5174.2007.00002.x

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: The Do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial

Autor: Peter M. DiBattiste, Jennifer A. White, Albert W. Chan, Peter B. Berger, Howard C. Herrmann, Patricia J.M. Best, Eric J. Topol, David J. Moliterno, Steen Dalby Kristensen

Publikováno v: Berger, PB, Best, PJ, Topol, EJ, White, J, DiBattiste, PM, Chan, AW, Kristensen, S D, Herrmann, HC & Moliterno, DJ 2005, ' The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro give similar efficacy outcome (TARGET) trial ', Am. Heart. J., vol. 149, no. 5, pp. 869-75 .

Background Renal function significantly impacts morbidity and mortality after a percutaneous coronary intervention. Platelet glycoprotein (GP) IIb/IIIa inhibitors reduce ischemic complications during percutaneous coronary intervention; little is know

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b400fec875d566050acadddd4ed9892b
https://doi.org/10.1016/j.ahj.2004.12.002